Trial of Liposomal Bupivacaine for TKA

Completed · Phase 4

Conditions studied: Knee Replacement, Total Knee Arthroplasty, Post-Operative Pain

In brief

Total knee arthroplasty (TKA), also known as a knee replacement, is a procedure performed to reduce severe pain and improve function of the joint. Managing postoperative pain can be challenging following TKA, and inadequate relief can lead to impaired mobility and persistent opioid use. Adductor canal nerve blocks (ACB), have shown significant benefit in improving postoperative analgesia and patient satisfaction. However, the local anesthetic used currently for these blocks only provides temporary relief that wears off within 24 hours. Liposomal bupivacaine is an extended-release local anesthetic agent that can provide up to 72 hours of pain relief, however it is unclear if its use is also effective in ACBs for knee surgery. The purpose of this study is to determine if liposomal bupivacaine is better than conventional bupivacaine in improving pain control, opioid consumption, and length of stay in patients scheduled for TKA.

Key facts

Study ID

NCT05635916

Run by

Northern Light Mercy Hospital

People needed

80

Starts

2022-09-22

Expected to finish

2023-04-17

Last updated by the study team

2023-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients 18 years and older who are scheduled for a total knee arthroplasty at Northern Light Mercy Hospital

You may not qualify if…

• Patients under the age of 18

Where it is running

• Northern Light Mercy Hospital — Portland, Maine, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.